Business
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
- Discussion of STRO-002 Data and Program Expansion at 5pm ET / 2pm PT on Dec. 3rd - SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 /PRNewswire/ -- Sutro
About this update from Sutro Biopharma, Inc.
[{"type":"text","content":"- Discussion of STRO-002 Data and Program Expansion at 5pm ET / 2pm PT on Dec. 3rd -\n\n\nSOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced today that it will host a live webcast event to provide a clinical update from the company's ongoing dose escalation Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC), for patients with ovarian cancer. The results presented will follow-up on previously presented data, based on a new data cut-off date of Oct. 30, 2020. The company will also give an update on the program expansion cohorts in ovarian and endometrial cancer. The virtual KOL Discussion of STRO-002 Data will be held on Thursday, Dec. 3, 2020, at 5pm ET / 2pm PT.\nThe data will be presented and discussed by Principal Investigators from two STRO-002 clinical trial sites: \nLainie P. Martin, M.D. - Leader, Gynecology/Oncology Program and Associate Professor of Medicine at Hospital of the University of Pennsylvania; Dr. Martin is also a member of Sutro's Clinical Advisory BoardR. Wendel Naumann, M.D. - Professor & Director of Gynecologic Oncology Research and Associate Medical Director of Clinical Trials at Levine Cancer Institute – Atrium Health in Charlotte, North Carolina; Dr. Naumann is also a member of Sutro's Clinical Advisory BoardTo register and access the Zoom link for this event click here or email Annie Chang at [email protected].\nAn archived recording of the event will be available through the Company Presentation page of the Investor section of the company's website at http://www.sutrobio.com for approximately 30 days.\nAbout the Phase 1 Trial of STRO-002 in Ovarian CancerSTRO-002-GM1, the Phase 1 open-label, multicenter, dose escalation trial with dose expansion of STRO-002, has completed enrollment. Follow-up is ongoing and will continue to evaluate the safety, tolerability, and preliminary anti-tumor activity of STRO-002 in adults with advanced epithelial ovarian cancer, including fallopian and primary peritoneal cancer. The trial is registered with clinicaltrials.gov identifier NCT03748186. Sutro discov...